Zydus Cadila receives final nod from USFDA for Tizanidine Tablets USP

13 Mar 2018 Evaluate

Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market Tizanidine Tablets USP in the strengths of 2 mg and 4 mg. The group now has more than 180 approvals and so far has filed over 320 ANDAs since the commencement of the filing process in FY 2003-04.

The drug is used to treat muscle spasms caused by certain conditions such as multiple sclerosis, spinal cord injury and works by helping to relax the muscles. It will be manufactured at the group's formulations manufacturing facility at SEZ in Ahmedabad.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

931.45 -3.75 (-0.40%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×